Study on in vitro biofilm formation ability of Acinetobacter baumannii

doi:10.16150/j.1671-2870.2019.05.009

Abstract

Abstract:

Objective: To study the in vitro biofilm formation ability of Acinetobacter baumannii for providing a reference for clinical prevention and treatment of Acinetobacter baumannii infection and control of its biofilm formation. Methods: One hundred and one strains of Acinetobacter baumannii isolated from infected patients at Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine from October to December 2017 were collected. The ability of the strains to form biofilm at different temperatures was detected by crystal violet staining; the antimicrobial susceptibility test was performed by Vitek2 Compact and the disc diffusion method. The carrying status of biofilm formation-related genes (bap, abaI, bfmS, csuAB, csuA, csuC, csuD, csuE, cpaA, and ompA) was detected by PCR. Results: The positive rate of Acinetobacter baumannii biofilm formation at 25 ℃ (93.1%) was significantly higher than that at 35 ℃ (60.4%) (P<0.05). There was a correlation between the resistance rate of isolates to Ampicillin/Sulbactam or Aminoglycosides and the biofilm formation ability (P<0.05); and there was no significant correlation between the biofilm formation ability and whether it carried the abovementioned 10 related genes (P>0.05). Conclusions: The biofilm formation ability of Acinetobacter baumannii is related to the culture temperature, and also correlated in some degree with the resistance rate to Ampicillin/sulbactam and Aminoglycosides. However, the biofilm formation ability is not related to the abovementioned 10 related genes (bap, abaI, etc.).

Key words: Acinetobacter baumannii, Biofilm, Crystal violet staining

CLC Number:

R372

HUANGFU Yuchan, DIAO Wenjing, YU Jing, LIU Ying, SHEN Lisong. Study on in vitro biofilm formation ability of Acinetobacter baumannii[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(05): 532-537.

Figures/Tables 4

References 25

[1]	Gonzalez-Villoria AM, Valverde-Garduno V. Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen[J]. J Pathog, 2016, 2016:7318075.
[2]	胡付品, 郭燕, 朱德妹, 等. 2017年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2018, 18(3):241-251.
[3]	Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious disea-ses[J]. Nat Rev Microbiol, 2004, 2(2):95-108. pmid: 15040259
[4]	Vatan A, Saltoglu N, Yemisen M, et al. Association between biofilm and multi/extensive drug resistance in diabetic foot infection[J]. Int J Clin Pract, 2018, 72(3):e13060. doi: 10.1111/ijcp.13060 URL
[5]	Babapour E, Haddadi A, Mirnejad R, et al. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance[J]. Asian Pac J Trop Biomed, 2016, 6(6):528-533. doi: 10.1016/j.apjtb.2016.04.006 URL
[6]	Tomaras AP1, Flagler MJ, Dorsey CW, et al. Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology[J]. Microbiology, 2008, 154(Pt 11):3398-3409. doi: 10.1099/mic.0.2008/019471-0 URL
[7]	Tomaras AP, Dorsey CW, Edelmann RE, et al. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chape-rone-usher pili assembly system[J]. Microbiology, 2003, 149(Pt 12):3473-3484. doi: 10.1099/mic.0.26541-0 URL
[8]	Aliramezani A, Douraghi M, Hajihasani A, et al. Clonal relatedness and biofilm formation of OXA-23-producing carbapenem resistant Acinetobacter baumannii isolates from hospital environment[J]. Microb Pathog, 2016, 99:204-208. doi: 10.1016/j.micpath.2016.08.034 URL
[9]	Vatan A, Saltoglu N, Yemisen M, et al. Association between biofilm and multi/extensive drug resistance in diabetic foot infection[J]. Int J Clin Pract, 2018, 72(3):e13060. doi: 10.1111/ijcp.13060 URL
[10]	Gurung J, Khyriem AB, Banik A, et al. Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit[J]. Indian J Crit Care Med, 2013, 17(4):214-218. doi: 10.4103/0972-5229.118416 URL
[11]	赖其伟, 黄丽芳. 不鲍曼不动杆菌生物被膜与耐药性的相关性分析[J]. 国际检验医学杂志, 2016, 37(2):153-154.
[12]	Gopal R, Kim YG, Lee JH, et al. Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains[J]. Antimicrob Agents Chemother, 2014, 58(3):1622-1629. doi: 10.1128/AAC.02473-13 URL
[13]	Qi L, Li H, Zhang C, et al. Relationship between Antibiotic Resistance, Biofilm Formation, and Biofilm-Specific Resistance in Acinetobacter baumannii[J]. Front Micro-biol, 2016, 7:483.
[14]	刘原, 柯蕊, 杨妮, 等. 呼吸道分离鲍曼不动杆菌生物被膜形成能力与耐药性关系的研究[J]. 中国实验诊断学, 2015, 19(8):1243-1246.
[15]	Wen H, Wang K, Liu Y, et al. Population dynamics of an Acinetobacter baumannii clonal complex during colonization of patients[J]. J Clin Microbiol, 2014, 52(9):3200-3208. doi: 10.1128/JCM.00921-14 URL
[16]	Abdi-Ali A, Hendiani S, Mohammadi P, et al. Assessment of Biofilm Formation and Resistance to Imipenem and Ciprofloxacin among Clinical Isolates of Acinetobacter baumannii in Tehran[J]. Jundishapur J Microbiol, 2014, 7(1):e8606.
[17]	Tilley D, Law R, Warren S, et al. CpaA a novel protease from Acinetobacter baumannii clinical isolates deregulates blood coagulation[J]. FEMS Microbiol Lett, 2014, 356(1):53-61. doi: 10.1111/1574-6968.12496 pmid: 24910020
[18]	Ghasemi E, Ghalavand Z, Goudarzi H, et al. Phenotypic and Genotypic Investigation of Biofilm Formation in Clinical and Environmental Isolates of Acinetobacter baumannii[J]. Arch Clin Infect Dis, 2018, 13(4):e12914.
[19]	Thummeepak R, Kongthai P, Leungtongkam U, et al. Distribution of virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter baumannii clini-cal isolates[J]. Int Microbiol, 2016, 19(2):121-129. doi: 10.2436/20.1501.01.270 pmid: 27845499
[20]	Fallah A, Rezaee MA, Hasani A, et al. Frequency of bap and cpaA virulence genes in drug resistant clinical isolates of Acinetobacter baumannii and their role in biofilm formation[J]. Iran J Basic Med Sci, 2017, 20(8):849-855.
[21]	Ali HM, Salem MZM, El-Shikh MS, et al. Investigation of the Virulence Factors and Molecular Characterization of the Clonal Relations of Multidrug-Resistant Acinetobacter baumannii Isolates[J]. J AOAC Int, 2017, 100(1):152-158. doi: 10.5740/jaoacint.16-0139 URL
[22]	Liu H, Wu YQ, Chen LP, et al. Biofilm-Related Genes: Analyses in Multi-Antibiotic Resistant Acinetobacter Baumannii Isolates From Mainland China[J]. Med Sci Monit, 2016, 22:1801-1807. doi: 10.12659/MSM.898959 URL
[23]	童飞, 汪跃国, 范骁钦. 2015-2016年重症监护病房鲍曼不动杆菌感染及耐药分析[J]. 安徽医学, 2017, 38(12):1583-1585.
[24]	Selasi GN, Nicholas A, Jeon H, et al. Differences in Biofilm Mass, Expression of Biofilm-Associated Genes, and Resistance to Desiccation between Epidemic and Sporadic Clones of Carbapenem-Resistant Acinetobacter baumannii Sequence Type 191[J]. PLoS One, 2016, 11(9):e0162576.
[25]	Marti S, Nait Chabane Y, Alexandre S, et al. Growth of Acinetobacter baumannii in pellicle enhanced the expression of potential virulence factors[J]. PLoS One, 2011, 6(10):e26030. doi: 10.1371/journal.pone.0026030 URL

引物名称	引物序列（5'→3'）	预期产物长度(bp)
bap	F-5′-TAG GGA GGG TAC CAA TGC AG R-5′-TCA TGA TTT GAT GCT GCA GCG ATA A	405
abaI	F-5'-GTA TTT GTT GAA TAT TTG GG R-5'-GTA ATG AGT TGT TTT GCG CC	362
bfmS	F-5'-ATA TAT GCG GGG CTG GTA ATT C R-5'-ATG CAG GTG CTT TTT TAT TGG T	1 621
csuAB	F-5'-ATG AAT ATG AAA AAC ATT CA R-5'-TTA GAA ATT TAC AGT GAC TA	543
csuA	F-5'-ATG AGT AGA CCT GTT TTA AA F-5'-TTA AAA CTC AAT CGT AAT TG	579
csuC	F-5'-ATG GTG ATT TGT ATG AAC AA R-5'-TCA TGA TGG ATC CTC CAT TT	834
csuD	F-5'-TTG TCG GGT GGA TGT TTA R-5'-TTG TGG CAA TGG ATA GGT	807
csuE	F-5'-ATG CAT GTT CTC TGG ACT GAT GTT GAC R-5'-CGA CTT GTA CCG TGA CCG TAT CTT GAT AAG	977
cpaA	F-5'-CTG CTT TAG GAA AAT GGG R-5'-CGC CTT CAA TCA TTC TAA G	669
ompA	F-5'-CAA TTG TTA TCT CTG GAG R-5'-ACC TTG AGT AGA CAA ACG A	952

判断结果	35 ℃		25 ℃		P值
判断结果	菌株数	比例（%）	菌株数	比例（%）	P值
强阳性（++）	12	11.9	10	9.9	0.651
阳性（+）	49	48.5	84	83.2	<0.001
阴性（-）	40	39.6	7	6.9	<0.001

药物名称	强阳性（n=12）		阳性（n=49）		阴性（n=40）		P值^a)
药物名称	株数	耐药率（%）	株数	耐药率（%）	株数	耐药率（%）	P值^a)
哌拉西林	11	91.7	45	91.8	38	95.0	0.751
氨苄西林/舒巴坦	7	58.3	45	91.8	35	87.5	0.021
头孢哌酮/舒巴坦	4	33.3	18	36.7	15	37.5	1.000
头孢曲松	11	91.7	45	91.8	38	95.0	0.751
头孢他啶	11	91.7	45	91.8	38	95.0	0.751
美罗培南	11	91.7	44	89.8	36	90.0	1.000
亚胺培南	11	91.7	44	89.8	36	90.0	1.000
阿米卡星	6	50.0	42	85.7	32	80.0	0.034
庆大霉素	7	58.3	45	91.8	30	75.0	0.009
妥布霉素	6	50.0	42	85.7	32	80.0	0.034
环丙沙星	11	91.7	45	91.8	38	95.0	0.751
左旋氧氟沙星	5	41.7	24	49.0	18	45.0	0.874^b)
复方新诺明	7	58.3	27	55.1	27	67.5	0.505
米诺环素	0	0.0	5	10.2	6	15.0	0.388